Home › Funds › Soleus Capital Management, L.P. › URGN
Soleus Capital Management, L.P. position in URGN
UROGEN PHARMA LTD · Health Care
Soleus Capital Management, L.P. reported holding 829,810 shares of URGN (UROGEN PHARMA LTD) in its Q2 2026 13F filing — a position valued at US$30.5M, representing 1.05% of its reported portfolio and ranking #29 among its reported holdings. Soleus Capital Management, L.P. has disclosed URGN holdings in 7 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s URGN position evolved
Soleus Capital Management, L.P. first disclosed a stake in URGN in Q3 2023 at 372,000 shares (US$5.2M). The position peaked in Q2 2026 at 829,810 shares, worth US$30.5M. Across 7 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 829,810 shares valued at US$30.5M — an increase of 102,810 shares quarter over quarter.. Notable position changes include a 69% trim in Q3 2025 (shares rose 17% over the following quarter), a 78% trim in Q4 2025 (shares fell 23% over the following quarter), a 385% increase in Q1 2026 (shares rose 105% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 372.00K | $5.21M | New |
| Q1 2024 | 10.00K | $150.00K | New |
| Q2 2025 | 2.19M | $29.93M | New |
| Q3 2025 | 679.00K | $13.55M | Reduce |
| Q4 2025 | 150.00K | $3.51M | Reduce |
| Q1 2026 | 727.00K | $13.07M | Add |
| Q2 2026 | 829.81K | $30.54M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About URGN and 13F data
URGN (UROGEN PHARMA LTD) is a Health Care company. 39 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$80.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding URGN
- RTW INVESTMENTS, LP 4.54M sh · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M sh · $89.58M · Q2 2026
- Jefferies Financial Group Inc. 2.20M sh · $80.95M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M sh · $61.58M · Q2 2026
- Opaleye Management Inc. 1.44M sh · $52.99M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.30M sh · $47.91M · Q2 2026
- MPM BioImpact LLC 933.41K sh · $34.35M · Q2 2026
- Boxer Capital Management, LLC 500.00K sh · $18.40M · Q2 2026
- Privium Fund Management B.V. 210.00K sh · $7.73M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 191.31K sh · $7.04M · Q2 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held URGN?
Soleus Capital Management, L.P. has disclosed URGN holdings in 7 of the last 12 reported quarters, going back to Q3 2023.
What is Soleus Capital Management, L.P.'s current position in URGN?
As of Q2 2026, Soleus Capital Management, L.P. holds 829.81K shares of URGN (UROGEN PHARMA LTD), valued at $30.54M, representing 1.05% of its reported portfolio and ranking #29.
Has Soleus Capital Management, L.P. been buying or selling URGN?
In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in URGN. The position peaked in Q2 2026 at 829.81K shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.